A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Pfizer
Cancer Research UK
Pfizer
Amgen
Tianjin Medical University
Hoffmann-La Roche
National Cancer Institute (NCI)
Cancer Research UK
Ikena Oncology
Eli Lilly and Company